Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 3/20 | 0.43 |
| ▸ | MERTK | Q12866 | 3/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14426306 | 0.92 | NOTUM (0.47) | AXLMERTKCYP2D6CSNK1DNOTUM | |
| SCHEMBL12315892 | 0.87 | NOTUM (0.51) | AXLMERTKCYP2D6CSNK1DHSD11B1 | |
| SCHEMBL12316015 | 0.87 | NOTUM (0.46) | HSD11B1NOTUMKDM1A | |
| SCHEMBL12316031 | 0.86 | HSD11B1 (0.39) | AXLMERTKCYP2D6CSNK1DHSD11B1 | |
| SCHEMBL12459986 | 0.84 | OPRL1 (0.46) | AXLMERTKCSNK1DHSD11B1NOTUM | |
| SCHEMBL13203952 | 0.84 | NOTUM (0.43) | HSD11B1NOTUMSLC18A3SIGMAR1 | |
| SCHEMBL12315863 | 0.83 | HSD11B1 (0.41) | HSD11B1NOTUMKDM1A | |
| SCHEMBL12316020 | 0.83 | KDM1A (0.50) | HSD11B1KDM1A | |
| SCHEMBL13203975 | 0.83 | NOTUM (0.42) | AXLMERTKCYP2D6CSNK1DHSD11B1 | |
| SCHEMBL12315864 | 0.81 | CHRM1 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263605-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2012-09-11 | — | — | US | disclosed |
| US-8263605-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2012-09-11 | — | — | US | disclosed |
| US-8263605-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2012-09-11 | — | — | US | disclosed |
| EP-1987034-B1 | SPIRO CONDENSED PIPERIDINES AS MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMA (US) | 2011-07-20 | — | — | EP | disclosed |
| EP-1987034-B1 | SPIRO CONDENSED PIPERIDINES AS MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMA (US) | 2011-07-20 | — | — | EP | disclosed |
| US-20090227614-A1 | Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2009-09-10 | — | — | US | disclosed |
| US-20090227614-A1 | Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2009-09-10 | — | — | US | disclosed |
| US-20090227614-A1 | Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2009-09-10 | — | — | US | disclosed |
| WO-2007100670-A1 | SPIRO CONDENSED PIPERIDNES AS MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227614-A1 | Modulators of Muscarinic Receptors | CHRM5, CHRM3, CHRM2 | AXL 1690/4885MERTK 670/4885CYP2D6 1013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.